Funding Incubator Research San Diego 
socalTECH
MAY 27, 2015
La Jollla-based MANTA Instruments , a developer of technology for characterizing nanoparticles, has raised a round of seed funding, from Triton Technology Fund. Size of the funding was not announced. The company is part of the EvoNexus startup incubator, and is led by Rick Cooper.
Xconomy
OCTOBER 1, 2018
VelosBio, a biotech startup researching new cancer drugs, has raised $58 million in financing. VelosBio joined Johnson & Johnson’s JLABS @ San Diego incubator in January. The new VelosBio cash, a Series A round of financing, was led by Arix Bioscience (LSE: ARIX ) and Sofinnova Ventures.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
socalTECH
MARCH 26, 2013
San Diego-based ZeaKal , a plant sciences startup focused on developing technology to increase the yield and oil content of crops, said this morning that it has raised $3.8M in a Series A funding. The round was led by Finestere Ventures, Two Oceans, and the Missouri Soybean Merchandising Council (MSMC). READ MORE>>.
Xconomy
OCTOBER 13, 2017
The idea in 2011 was to create a space at what was then Johnson & Johnson’s pharmaceutical research and development facility in San Diego for an “innovation center,” a place where 18 to 20 life sciences startups could incubate, replete with lab space and equipment. The first JLABS incubator opened here.
TechCrunch LA
MARCH 22, 2018
Our research revealed a saturation level causing unprecedented challenges, starting with exorbitant housing prices and runaway operating costs that accelerate a startup’s “burn rate”—its monthly spending. In fact, as is well-reported, the luster of Silicon Valley is fading.
socalTECH
AUGUST 7, 2017
San Diego-based Scientist.com , the venture-backed, online marketplace for outsourced research, and biotech accelerator IndieBio announced this morning that the two are in a new partnership. READ MORE>>.
Xconomy
SEPTEMBER 27, 2016
[ Note: The headline has been corrected to better describe the company’s type of funding. Fortis Therapeutics, a new San Diego biotech, has raised $18 million in initial funding to develop drugs for hard-to-treat prostate and bone marrow cancers. 9/27/16, 2:09 p.m. Reprints | Share: UNDERWRITERS AND PARTNERS.
Expert insights. Personalized for you.
100 
Let's personalize your content